UNSPSC 51314371: Fexofenadine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314371 Fexofenadine/pseudoephedrine is a Commodity code that captures state and local procurement of pharmaceuticals and over-the-counter products, though recent solicitations tagged under this code show a broader scope including naloxone, drug deactivation systems, and generic multi-source pharmaceuticals rather than the specific antihistamine-decongestant combination the code name denotes. State and local governments procure these items to support community health programs, pharmacy benefit plans, and public health initiatives. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering purchases across Minnesota, Oregon, and participating jurisdictions). Cooperative purchasing vehicles play a significant role, particularly MMCAP, which coordinates procurement for multiple state and local government facilities under a single contract framework.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, soliciting 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida; the contract includes a two-year initial term with a one-year renewal option and is potentially FEMA-funded. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription fulfillment programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products; vendors must work through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), comply with cGMP and Drug Supply Chain Security Act requirements, and maintain pricing flexibility across flat and net pricing models, with awards effective July 1, 2026.